行情

AIM

AIM

AIM ImmunoTech Inc
AMEX

实时行情|Nasdaq Last Sale

2.050
-0.040
-1.91%
盘后: 2.070 +0.02 +0.98% 17:37 03/05 EST
开盘
2.040
昨收
2.090
最高
2.090
最低
1.930
成交量
169.73万
成交额
--
52周最高
7.11
52周最低
1.600
市值
8,340.73万
市盈率(TTM)
-4.6171
分时
5日
1月
3月
1年
5年
雷达测高仪市场增长2021年行业份额和规模,主要发现的变化,COVID-19影响,最新趋势分析,到2027年的进展状况和收入预期研究报告
Mar 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Radar Altimeters Market”...
The Express Wire · 3天前
AIM ImmunoTech在胰腺癌中获得了Ampligen的孤儿药标签
Benzinga · 02/24 18:57
2021年全球飞机传感器市场规模|预计到2026年的国家预期增长值,行业细分,SWOT分析,主要参与者概况,收入和市场份额
Feb 22, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Aircraft Sensors Market” research...
The Express Wire · 02/22 09:46
AIM ImmunoTech报告其伦理委员会已批准开始进行氨苄青霉素作为鼻内治疗的第一阶段研究
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an
Benzinga · 02/16 14:36
2021年全球飞机空速指标市场增长分析报告:全球行业规模,市场需求和即将发展,当前趋势,到2027年顶级公司研究预测
Feb 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Aircraft Airspeed Indicators Market”...
The Express Wire · 02/16 08:49
AIM ImmunoTech宣布荷兰卫生和青年保健检查局已批准对6名胰腺癌患者的治疗,这是早期抢救计划的一部分
OCALA, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six pancreatic cancer patients as part of a
Benzinga · 02/10 14:16
AIM ImmunoTech(AIM)收到美信集团的收购
Maxim Group analyst Jason McCarthy maintained a Buy rating on AIM ImmunoTech (AIM) on March 26 and set a price target of $2.00. The company's shares
SmarterAnalyst · 02/09 09:07
The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 28)
Benzinga · 01/29 12:45
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AIM最新的财务预测,通过AIM每股收益,每股净资产,每股现金流等数据分析AIM ImmunoTech Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AIM价格均价为6.33,最高价位7.50,最低价为5.00。
EPS
机构持股
总机构数: 15
机构持股: 9.35万
持股比例: 0.23%
总股本: 4,068.65万
类型机构数股数
增持
6
31
建仓
4
7.09万
减持
2
2,899
平仓
7
1.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.94%
制药与医学研究
+1.63%
高管信息
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
暂无数据
AIM 简况
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

微牛提供AIM ImmunoTech Inc(AMEX-AIM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AIM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AIM股票基本功能。